Long-Term Clinical Outcomes after Early Initiation of RRT in Critically Ill Patients with AKI

J Am Soc Nephrol. 2018 Mar;29(3):1011-1019. doi: 10.1681/ASN.2017060694. Epub 2017 Dec 1.

Abstract

Whether earlier initiation of RRT in critically ill patients with AKI can improve outcomes remains debated. We examined follow-up data from a large clinical trial to prospectively investigate the long-term outcomes associated with the timing of RRT initiation in such patients. We extended the follow-up of patients in the Early Versus Delayed Initiation of RRT in Critically Ill Patients with AKI (ELAIN) Trial from 90 days to 1 year after randomization for 230 (99.6%) patients. The primary outcome was a composite of major adverse kidney events (persistent renal dysfunction, dialysis dependence, and mortality) at 1 year. Secondary outcomes included inflammatory markers. Overall, 72 of 111 (64.9%) and 106 of 119 (89.1%) patients met the primary outcome in the early (stage 2 AKI) and delayed (stage 3 AKI) initiation groups, respectively (odds ratio [OR] with early initiation, 0.23; 95% confidence interval [95% CI], 0.11 to 0.45; P< 0.001). The early initiation group had a 1-year all-cause mortality rate (56 of 111 [50.2%]) significantly lower than that of the delayed initiation group (83 of 119 [69.8%]; absolute difference, -19.6%; 95% CI, -32.0% to -7.2%; P<0.01). After 1 year, 16 of 55 (29.1%) and 23 of 36 (63.9%) surviving patients in the early and delayed groups, respectively, failed to recover renal function (absolute difference, -34.8%; 95% CI, -54.6% to -15.0%; P=0.001). In conclusion, early initiation of RRT in these critically ill patients with AKI significantly reduced the occurrence of major adverse kidney events, reduced mortality, and enhanced renal recovery at 1 year.

Keywords: acute renal failure; hemodialysis; survival.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Kidney Injury / complications
  • Acute Kidney Injury / physiopathology
  • Acute Kidney Injury / therapy*
  • Aged
  • Aged, 80 and over
  • Biomarkers / blood
  • Critical Illness
  • Follow-Up Studies
  • Humans
  • Inflammation / blood
  • Interleukin-10 / blood
  • Interleukin-18 / blood
  • Interleukin-6 / blood
  • Interleukin-8 / blood
  • Interleukins / blood*
  • Intramolecular Oxidoreductases / blood*
  • Macrophage Migration-Inhibitory Factors / blood*
  • Mortality
  • Recovery of Function
  • Renal Insufficiency, Chronic / etiology*
  • Renal Insufficiency, Chronic / physiopathology
  • Renal Insufficiency, Chronic / therapy*
  • Renal Replacement Therapy
  • Time Factors
  • Time-to-Treatment*

Substances

  • Biomarkers
  • CXCL8 protein, human
  • IL10 protein, human
  • IL6 protein, human
  • Interleukin-18
  • Interleukin-6
  • Interleukin-8
  • Interleukins
  • Macrophage Migration-Inhibitory Factors
  • Interleukin-10
  • Intramolecular Oxidoreductases
  • MIF protein, human